A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.
Evaluate the safety and tolerability of ZG19018 in Patients with KRAS G12C mutant advanced solid tumors.
KRAS G12C Mutant Advanced Solid Tumors
DRUG: ZG19018
Dose Limiting Toxicity (DLT), A DLT is defined as any Grade â‰¥ 3 AE meeting the criteria listed below occurring during the first treatment cycle of ZG19018 (day 1 through day 21) where elationship to ZG19018 cannot be ruled out., Up to 21Days|Objective Response Rate (ORR), The sum of the proportions of subjects who achieved CR or PR in imaging evaluation as assessed by the investigator based on RECIST1.1 criteria., Up to 24 Months
Evaluate the safety and tolerability of ZG19018 in Patients with KRAS G12C mutant advanced solid tumors.